Topotargets meets primary endpoint!

Topotarget exceeds primary endpoints........, Company Announcement Positive subtype data from the BELIEF trial presented at the 12th International Conference on Malignant Lymphoma To NASDAQ OMX Copenhagen A/S Announcement no. 18-13 / Copenhagen, June 17, 2013 Topotarget announces that positive subtype data on angioimmunoblastic T-cell lymphoma (AITL) from the BELIEF trial with belinostat in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL) will be presented at the 12th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland, on June 19-22, 2013. The belinostat abstract, which will be presented orally at the ICML conference, puts special emphasis to the BELIEF trial’s subtype AITL, which has shown an objective response rate (ORR) of 45.5%. The abstract further concludes that the favorable safety profile observed warrants further investigation of belinostat-based regimens to optimize outcomes for AITL. “The PTCL subtype, AITL, represents [mehr]

aktiencheck.de - Forum - TOPOTARGET A/S COPEN

Topotargets meets primary endpoint!